CA1221635A - Composition with an improved pharmaceutical activity and use as veterinary drug - Google Patents
Composition with an improved pharmaceutical activity and use as veterinary drugInfo
- Publication number
- CA1221635A CA1221635A CA000453413A CA453413A CA1221635A CA 1221635 A CA1221635 A CA 1221635A CA 000453413 A CA000453413 A CA 000453413A CA 453413 A CA453413 A CA 453413A CA 1221635 A CA1221635 A CA 1221635A
- Authority
- CA
- Canada
- Prior art keywords
- antibiotic
- compound
- type
- oxytetracycline
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000000694 effects Effects 0.000 title description 3
- 239000000273 veterinary drug Substances 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 claims abstract description 21
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 20
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 10
- 239000004100 Oxytetracycline Substances 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 229960000625 oxytetracycline Drugs 0.000 claims abstract description 8
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims abstract description 8
- 235000019366 oxytetracycline Nutrition 0.000 claims abstract description 8
- 230000002195 synergetic effect Effects 0.000 claims abstract description 8
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019371 penicillin G benzathine Nutrition 0.000 claims abstract description 7
- 229940056360 penicillin g Drugs 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 108010078777 Colistin Proteins 0.000 claims description 3
- 229960001127 colistin sulfate Drugs 0.000 claims description 3
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims 2
- 229940049954 penicillin Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 claims 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 abstract description 2
- 230000001338 necrotic effect Effects 0.000 abstract description 2
- 241000607142 Salmonella Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010017564 Fusobacterium infections Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028846 Necrobacillosis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000595586 Coryne Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une composition antibiotique comprenant, sous une forme injectable, un mélange synergique d'un antibiotique du type oxytétracycline et d'un antibiotique du type benzylpénicilline en vue de combattre certaines maladies dues à des bactéries, caractérisée en ce qu'elle comporte outre les deux antibiotiques susdits, également un antibiotique du type Multimycine dans un rapport pondéral oxytétracycline: benzylpénicilline: Multimycine compris dans une plage variant de 10 à 30 du premier composé, 90 à 70 du deuxième composé et 1 à 15 du troisième composé. Cette composition exerce une action combinée synergique susceptible de guérir les maladies nécrotiques et les affections des muqueuses pour lesquelles il n'existe pas à ce jour de remèdes valables.The invention relates to an antibiotic composition comprising, in an injectable form, a synergistic mixture of an antibiotic of the oxytetracycline type and of an antibiotic of the benzylpenicillin type for the purpose of combating certain diseases due to bacteria, characterized in that it comprises in addition to the two above-mentioned antibiotics, also an antibiotic of the Multimycin type in an oxytetracycline: benzylpenicillin: Multimycin weight ratio comprised in a range varying from 10 to 30 of the first compound, 90 to 70 of the second compound and 1 to 15 of the third compound. This composition exerts a combined synergistic action capable of curing necrotic diseases and affections of the mucous membranes for which there are no valid remedies to date.
Description
, `~ 1 La présente invention est relative à une composition antibiotique comprenant, sous une forme injectable, un mélan- -ge synergique d'un antibiotique du type oxyt~tracycline et d'un antibiotique du type benzylpénicilline en vue de combattre certaines maladies dues à des bactéries.
L'usage des antibiotiques s'est largement répandu et un grand nombre d'antibiotiques différents à effet spécifique particulier ou à large spectre d'action sont actuellement disponibles sur le marché.
Ces antibiotiques sont actuellement largement utilisés pour le traitement de mammi~ères , notamment en médecine vétérinaire.
Pour diverses raisons, on s'aperçoit qu'un grand nombre de produits ne peuvent pas combattre certaines affections, en particulier des maladies infectleuses ou encore qu'ils perdent leur efficacit~, vraisembla-blement par suite de modifications des souches micro-biennes, virales ou cryptogamiques. `~
On sait par le brevet belge N 5050709 ~PFIZER)que des compositions antibiotiques contenant simultanément un antibiotique du type oxytétracycline ou terramycine et un antibiotique du type pénicilline sont étonnamment efficaces contre maints types différents de bactéries, ~ `'~ '~
1~1tj3S
, en particulier contre ~ivers microorganismes infectieux des groupes Salmonella et Pseudomonas, alors qu'em-ployés individuellement ceux-ci n'ont qu'une faible valeur thérapeutique vis-à-vis desdits microorganismes.
Parmi les maladies causées par les Salmonella, on peut citer pour l'homme, la fièvre paratypho~de, la septicémie salmonellique, l'entérocolite salmonellique, la pneumonie et l'ostéomyélite. Certaines ~actéries du groupe des ~::
Salmonella sont aussi la cause de maladies dangereuses chez les animaux 9 telle l'infection due au Salmonella pullorum de la volaille.
La présente invention est également basée sur l'ob-tention d'une synergie surprenante des deux antibiotiques susdits.
~lle est basée sur la découverte que l'adjonction ~ ~:
de sulfate de colistine ou Multimycine à un mélange~ ~x anihci~E~susdits élargit, de façon remarquable~les . .
spectres d'applicabilité de la compositlon et fournit ~:
une composition susceptible de guérir des affections :
pour lesquelles il n'existe pas à ce jour de remèdes valables.
Elle est relative à une composition antibiotique comprenant, sous une forme in~ectable9 un mélange syner-gique d'un antibiotique du type oxytétracycline et d'un antibiotique du type benzylpénicilline en ~ue de combattre certaines maladies dues à des bactéries, essentiellement caractéris~e en ce qu'elle comporte, .
outre les deux antibiotiques susdits, é~alement un antibiotique du type M~ltimycine dans un rapport pon-d~ral oxytétracycline : benzylpénicilline : Multimycine compris dans une plage variant de 10 à ~0, de pr~f~rence - - - - .
'': . , ; :., 1~1f~3S
.
20 du premier composé, 90 à 70, de préférence ~0 du deuxième composé et 1 à 15, de préférence 7 du troisième composé.
La composition synergique de l'invention trouve son application vétérinaire préférée, compte tenu de son efficacité, pour combattre toutes les infections des muqueuses, en particulier les mycoses provoquées par des champignons et toutes les maladies nécrotiques, par exemple la nécrose, la nécrobacillose linguale des veaux et le chancre.
Un autre champ d'application est constitué par le traitement de la péritonite, de la métrite, de la pneumonie infectieuse des poulains (coryne bactéries-grippe) et le " blanc mal chez les bovins " ~ulcères sur les sahots) ou panaris.
Ces champs d'applications ne sont cependant pas limitatifs, car d'autres affections du même genre pewent être traitées efficacement à l'aide de la composition de l'invention.
L'invention sera décrite plus en détail à l'aide d'un exemple destiné à illustrer son caractère nouveau et inventif, sans que cependant nl la composition précise ni la forme galénique ne doivent être considérées comme une limitation.
' On a préparé une forme galénique de la composition antibiotique suivant l'invention en mélangeant pour 100 ml les constituants suivants :
~/ Chlorhydrate d'oxyt~tracycline 926 mg , `~ 1 The present invention relates to a composition antibiotic comprising, in an injectable form, a mixture -synergistic age of an antibiotic of the oxyt ~ tracycline type and a benzylpenicillin antibiotic for fight certain diseases caused by bacteria.
The use of antibiotics has spread widely and a lot of different antibiotics with effect specific specific or broad spectrum of action are currently available on the market.
These antibiotics are currently widely used for the treatment of mammals, in particular in veterinary medicine.
For various reasons, we find that a large many products cannot fight certain ailments, especially infectious diseases or that they lose their effectiveness ~, presumably due to changes in micro- strains biennes, viral or cryptogamic. `~
We know from Belgian patent N 5050709 ~ PFIZER) that antibiotic compositions containing simultaneously an antibiotic such as oxytetracycline or terramycin and a penicillin-type antibiotic are surprisingly effective against many different types of bacteria, ~ `` ~ '~
1 ~ 1tj3S
, especially against ~ various infectious microorganisms Salmonella and Pseudomonas groups, while em-individually folded these have only a slight therapeutic value vis-à-vis said microorganisms.
Among the diseases caused by Salmonella, one can quote for man, paratyphoid fever, sepsis salmonellosis, salmonella enterocolitis, pneumonia and osteomyelitis. Some ~ acteries of the group of ~ ::
Salmonella are also the cause of dangerous diseases in animals 9 such as Salmonella infection poultry pullorum.
The present invention is also based on the ob-a surprising synergy of the two antibiotics above.
~ It is based on the discovery that the addition ~ ~:
colistin sulfate or Multimycin to a mixture ~ ~ x anihci ~ E ~ aforesaid widens, remarkably ~ them. .
spectra of applicability of the compositlon and provides ~:
a composition capable of curing ailments:
for which there are no remedies to date valid.
It relates to an antibiotic composition comprising, in an in ~ ectable9 form a syner- mixture an antibiotic of the oxytetracycline type and of a benzylpenicillin type antibiotic in ~ eu fight certain diseases caused by bacteria, essentially characterized in that it comprises,.
in addition to the above two antibiotics, also ~
antibiotic type M ~ ltimycin in a pon-d ~ ral oxytetracycline: benzylpenicillin: Multimycin included in a range varying from 10 to ~ 0, pr ~ f ~ rence - - - -.
'':. ,; :., 1 ~ 1f ~ 3S
.
20 of the first compound, 90 to 70, preferably ~ 0 of second compound and 1 to 15, preferably 7 of the third compound.
The synergistic composition of the invention finds their preferred veterinary application, given its effectiveness, to fight all infections mucous membranes, especially yeast infections caused by fungi and all necrotic diseases, for example necrosis, lingual necrobacillosis of calves and canker.
Another field of application is the treatment of peritonitis, metritis, Infectious pneumonia in foals (coryne bacteria-flu) and "white sickness in cattle" ~ ulcers on sahots) or panaris.
However, these fields of application are not limiting, because other ailments of the same kind pewent be effectively treated using the composition of the invention.
The invention will be described in more detail using an example to illustrate its novelty and inventive, without however nl the composition precise nor the dosage form should be considered as a limitation.
'' A dosage form of the composition was prepared antibiotic according to the invention by mixing for 100 ml the following constituents:
~ / Oxyt hydrochloride ~ tracycline 926 mg
2/ ProcaIne Benzylpénicilline24000mg 2 / ProcaIne Benzylpenicillin24000mg
3/ Sulfate de colistine 10à100 mg ( antibioti~ue de type Multimycine) 3 / Colistin sulfate 10 to 100 mg (Multimycin type antibiotic)
4/ Polyvidone constituant du solvant :: .. ~ . . . . , --` ` lZ;~1t;35 4 / Polyvidone constituting the solvent :: .. ~. . . . , --` `lZ; ~ 1t; 35
5/ Magnes. formaldehyd bisulfis. 7 mg Oxyde de magn~sium 7 mg Para-hydroxybenzoate de ~thyle 68 mg Citrate de sodium (Vitamine A) 3,5 mg Sel de sodium de carboxymethylcellulose diluant Para-hydroxybenzoate de propyle 12 mg Polyvinyl pyrrolidone diluant 5 / Magnes. formaldehyd bisulfis. 7 mg Magnesium oxide 7 mg ~ Methyl para-hydroxybenzoate 68 mg Sodium citrate (Vitamin A) 3.5 mg Thinning salt of carboxymethylcellulose diluent Propyl para-hydroxybenzoate 12 mg Polyvinyl pyrrolidone diluent
6/ Propyleneglycol 12mg en tant que solvant 6 / Propyleneglycol 12mg as solvent
7/ eau distillée ad 100 ml Le mélange est réalisé d'abord en mélangeant entre eux les composés 1l et 2/~ ensuite en y ajoutant le composé 3/, après quoi tous les composés repris sous 4/ et 5/ y sont ajoutés.
La préparation sous forme liquide aux dosages in- ~-diqués ci-dessus est injectée à raison de 20 ml par 100 kg de poids corporel à des veaux, le dosage pouvant aller jusqu'à 50 ml par t~te de bétail adulte.
Ce dosage représente pour 20 ml, 6,25 millions d'UI d'antibiotioues.
La composition décrite s'est révélée particulière-ment efficace pour combattre les infections des muqueuses en particulier les mYcoses provoquées par des champignons qui, dans de nombreux cas~auraient~en l'absence du trai-tement à l'aide de la composition synergique de l'inven-tion,nécessité l'abattage du bétail ou des interventions chirurgicales. Une jeune b~te fortement atteinte de ., :~
. ~ . ; .- . ~ . :
. ~ , nécrobacillose llnguale et qui refusait de boire, a pu ~tre guérie endéans les 24 heures.
La composition s'est révélée également très effi-cace pour le traitement des autres affections signalées ci-dessus, alors que l'utilisation des antibiotiques cités isolément ne présente pratiquement pas d'effet.
Il convient de noter qu'en variante, il est possible d'ajouter au mélange synergique décrit d'autres antibio-tiquesJbien que ceux-ci, pour la plupart des composés connus, ne semblent pas accroltre l'efficacité de la composition synergique de 1'invention.
Il doit ~tre bien entendu que de nombreuses m~cat~ns peuvent etre apportées a la forme d'exécution de l'in-vention qui a été décrite et que l'homme de métier notam-ment peut apporter de nombreuses variantes dans le choix notamment des excipients, supports ou diluants. ~n principe donc, 1'invention couvre toutes les composi-tions synergiques de 1'invention avec les supports, diluants et excipients utilisés habituellement en phar-macologie.
Il convient de noter que la plage d'application mentionnée est donnée à titre d'exemple et n'est -nullement limitative. D~ mame, la posologie particulière à chaque espèce peut être variée et les préparations de l'invention trouvent leur application aussi bien à titre pr~venti~ qu'à titre curatif, dans des interventions chirurgicales, etc.
L'in~ention s'étend à toutes ces variantes d'appli-cation, de composition ou de préparation. 7 / distilled water ad 100 ml The mixing is carried out first by mixing between them compounds 1l and 2 / ~ then adding the compound 3 /, after which all of the compounds listed under 4 / and 5 / are added to it.
Preparation in liquid form for dosages in- ~ -described above is injected at the rate of 20 ml per 100 kg of body weight to calves, the dosage can up to 50 ml per head of adult cattle.
This dosage represents for 20 ml, 6.25 million of antibiotics.
The composition described was found to be particular-effective in fighting mucosal infections especially fungal infections which in many cases ~ would have ~ in the absence of treatment using the synergistic composition of the invention tion, need to slaughter livestock or interventions surgical. A young animal severely affected by .,: ~
. ~. ; .-. ~. :
. ~, necrobacillosis llnguale and who refused to drink, was able ~ be cured within 24 hours.
The composition was also very effective.
cace for the treatment of other reported conditions above, while the use of antibiotics cited in isolation has practically no effect.
It should be noted that as a variant, it is possible to add to the synergistic mixture described other antibiotics ticks Although these, for most of the compounds known, do not appear to increase the effectiveness of synergistic composition of the invention.
It should be understood that many cat ~ ns can be made to the embodiment of the which has been described and that the skilled person in particular many options can be chosen in particular excipients, carriers or diluents. ~ n in principle therefore, the invention covers all the compounds synergistic aspects of the invention with the supports, diluents and excipients usually used in phar-macology.
It should be noted that the range of application mentioned is given by way of example and is not -in no way limitative. Same, the particular dosage to each species can be varied and the preparations of the invention find application as well as foreseen only as a curative, in interventions surgical, etc.
In ~ ention extends to all these variants of appli-cation, composition or preparation.
Claims (7)
des bactéries, caractérisée en ce qu'elle comporte outre les deux antibiotiques susdits, également un antibiotique du type Multimycine dans un rapport pondéral oxytétracycline: benzyl-pénicilline: Multimycine compris dans une plage variant de 10 à 30 du premier composé, 90 à 70 du deuxième composé et 1 à 15 du troisième composé. 1. Antibiotic composition comprising, under a injectable form, a synergistic blend of an antibiotic from oxytetracycline type and a benzyl- type antibiotic penicillin to fight certain diseases caused by bacteria, characterized in that it comprises, in addition to two aforementioned antibiotics, also an antibiotic of the type Multimycin in an oxytetracycline: benzyl- weight ratio penicillin: Multimycin included in a range varying from 10 to 30 of the first compound, 90 to 70 of the second compound and 1 to 15 of the third compound.
1/ Chlorhydrate d'oxytétracycline 926 mg 2/ Procaîne Benzylpénicilline 24000 mg 3/ Sulfate de colistine (antibiotique du type Multimycine) 10 à 100 mg 3. Composition according to claim 1, charac-terized in that it corresponds to the galenical formula obtained by mixing the following constituents for 100 ml:
1 / Oxytetracycline hydrochloride 926 mg 2 / Procain Benzylpenicillin 24000 mg 3 / Colistin sulfate (antibiotic Multimycin type) 10 to 100 mg
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU84786 | 1983-05-03 | ||
| LU84786 | 1983-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1221635A true CA1221635A (en) | 1987-05-12 |
Family
ID=19730090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000453413A Expired CA1221635A (en) | 1983-05-03 | 1984-05-02 | Composition with an improved pharmaceutical activity and use as veterinary drug |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0150186A1 (en) |
| JP (1) | JPH01500746A (en) |
| CA (1) | CA1221635A (en) |
| DK (1) | DK3585D0 (en) |
| IE (1) | IE57352B1 (en) |
| IT (1) | IT1180166B (en) |
| PT (1) | PT78540B (en) |
| WO (1) | WO1984004249A2 (en) |
| ZA (1) | ZA843277B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038521A1 (en) * | 1998-02-02 | 1999-08-05 | Boehringer Ingelheim Vetmedica Gmbh | The use of combinations of active agents consisting of antimicrobially active substances and plant extracts containing terpene in veterinary medicine |
| BRPI0817299A8 (en) * | 2007-09-25 | 2019-01-29 | Pastoral Greenhouse Gas Res Limited | vaccines and vaccine components for microbial cell inhibition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE505709A (en) * | ||||
| FR1602275A (en) * | 1967-12-18 | 1970-11-02 | Tetracycline derivs antibiotics | |
| FR2364653A1 (en) * | 1976-09-20 | 1978-04-14 | Synthelabo | Synergistic antibiotic mixts. - contg. colistin and benzathine benzyl penicillin |
-
1984
- 1984-05-02 JP JP59501885A patent/JPH01500746A/en active Pending
- 1984-05-02 ZA ZA843277A patent/ZA843277B/en unknown
- 1984-05-02 CA CA000453413A patent/CA1221635A/en not_active Expired
- 1984-05-02 EP EP84901729A patent/EP0150186A1/en not_active Withdrawn
- 1984-05-02 IT IT20759/84A patent/IT1180166B/en active
- 1984-05-02 IE IE1088/84A patent/IE57352B1/en not_active IP Right Cessation
- 1984-05-02 WO PCT/BE1984/000012 patent/WO1984004249A2/en not_active Ceased
- 1984-05-03 PT PT78540A patent/PT78540B/en not_active IP Right Cessation
-
1985
- 1985-01-03 DK DK3585A patent/DK3585D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT78540B (en) | 1986-07-14 |
| ZA843277B (en) | 1984-12-24 |
| EP0150186A1 (en) | 1985-08-07 |
| IE841088L (en) | 1984-11-03 |
| JPH01500746A (en) | 1989-03-16 |
| PT78540A (en) | 1984-06-01 |
| WO1984004249A3 (en) | 1985-03-14 |
| DK3585A (en) | 1985-01-03 |
| DK3585D0 (en) | 1985-01-03 |
| WO1984004249A2 (en) | 1984-11-08 |
| IT8420759A0 (en) | 1984-05-02 |
| IT1180166B (en) | 1987-09-23 |
| IT8420759A1 (en) | 1985-11-02 |
| IE57352B1 (en) | 1992-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4301145A (en) | Antiseptic skin cream | |
| EP0022046A1 (en) | Drug composition based on plants and process for its preparation | |
| EP2165704B1 (en) | Use of alverine for the treatment of cutaneous affections | |
| RU98101105A (en) | NEW APPLICATION FOR MEDICAL PURPOSES | |
| CN100335062C (en) | Use of Ginkgo biloba flavonoidic extract substantially devoid or terpenes for oral hygiene and composition contg. same | |
| CA1221635A (en) | Composition with an improved pharmaceutical activity and use as veterinary drug | |
| HU200914B (en) | Process for producing new medical dosage unit suitable for local treatment of fungus infection of nails | |
| FR2494115A1 (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF BACTERIAL INFECTIONS IN ANIMALS, CONTAINING HALOGENO-6B PENICILLANIC SALT OR DERIVATIVE AND ONE OR MORE B-LACTAM ANTIBIOTICS | |
| JPS59205321A (en) | Anthelmintic synergistical novel composition | |
| FR2558058A1 (en) | Metronidazole based dermatological compositions for external topical use, which are useful in the treatment of acne | |
| EP0919239A1 (en) | Pharmaceutical composition for the treatment of acute gastroenteritis comprising a rehydration solution.and a compound with synergistic action | |
| RU2205011C1 (en) | Pharmaceutical composition eliciting antibacterial activity | |
| FR2833173A1 (en) | ANTIPYRETIC PREPARATION CONTAINING XYLITOL | |
| US3894153A (en) | Method of medical treatment of asthma | |
| KR100203704B1 (en) | Veterinary Treatment | |
| EP0063773A1 (en) | Orally active tolciclate and tolnaftate | |
| FR2741532A1 (en) | NOVEL PHARMACEUTICAL COMPOSITIONS WITH ANTIMIGRAINE ACTION AND THEIR PREPARATION METHOD | |
| CA2079328C (en) | Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof | |
| BE505709A (en) | ||
| FR2516795A1 (en) | MEDICAMENT FOR THE TREATMENT OF RESPIRATORY DISEASES COMPRISING A MEDICAMENT AGAINST RESPIRATORY DISEASES AND A HYDROXYCYCLOHEXYLAMINE OR ONE OF ITS SALTS | |
| FR2684297A1 (en) | USE OF SULFUR AMINO ACID FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ECZEMA. | |
| IE83642B1 (en) | Veterinary treatment | |
| EP0214947A1 (en) | Antalgic and anti-inflammatory composition for the treatment of arthrosis | |
| FR2646352A1 (en) | Novel pharmaceutical compositions for the treatment of constipation and process for obtaining them | |
| LU83561A1 (en) | ZOOTECHNIC COMPOSITIONS CONTAINING, ON THE ONE HAND, ZERANOL AND ON THE OTHER HAND, A 4,9,11-TRIENIC STEROID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |